Ex Vivo Expansion of Human Outgrowth Endothelial Cells Leads to IL-8-Mediated Replicative Senescence and Impaired Vasoreparative Function by Medina, Reinhold J. et al.
Ex Vivo Expansion of Human Outgrowth Endothelial Cells Leads
to IL-8-Mediated Replicative Senescence and Impaired
Vasoreparative Function
Medina, R. J., O'Neill, C. L., O'Doherty, T. M., Chambers, S. E. J., Guduric-Fuchs, J., Neisen, J., ... Stitt, A. W.
(2013). Ex Vivo Expansion of Human Outgrowth Endothelial Cells Leads to IL-8-Mediated Replicative




Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright © 2013 AlphaMed Press
Open Access
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:16. Feb. 2017
TISSUE-SPECIFIC STEM CELLS
Ex Vivo Expansion of Human Outgrowth Endothelial Cells
Leads to IL-8-Mediated Replicative Senescence and Impaired
Vasoreparative Function
REINHOLD J. MEDINA,a CHRISTINA L. O’NEILL,a T. MICHELLE O’DOHERTY,a SARAH E.J. CHAMBERS,a
JASENKA GUDURIC-FUCHS,a JESSICA NEISEN,b DAVID J. WAUGH,b DAVID A. SIMPSON,a ALAN W. STITTa
aCentre for Vision and Vascular Science and bCentre for Cancer Research and Cell Biology, School of Medicine,
Dentistry, and Biomedical Science, Queen’s University Belfast, Belfast, United Kingdom
Key Words. Angiogenesis • Cell therapy • Endothelial progenitor • IL8 • Senescence
ABSTRACT
Harnessing outgrowth endothelial cells (OECs) for vasore-
parative therapy and tissue engineering requires efficient
ex vivo expansion. How such expansion impacts on OEC
function is largely unknown. In this study, we show that
OECs become permanently cell-cycle arrested after ex
vivo expansion, which is associated with enlarged cell size,
b-galactosidase activity, DNA damage, tumor suppressor
pathway activation, and significant transcriptome changes.
These senescence hallmarks were coupled with low
telomerase activity and telomere shortening, indicating
replicative senescence. OEC senescence limited their
regenerative potential by impairing vasoreparative proper-
ties in vitro and in vivo. Integrated transcriptome-
proteome analysis identified inflammatory signaling path-
ways as major mechanistic components of the OEC senes-
cence program. In particular, IL8 was an important
facilitator of this senescence; depletion of IL8 in OECs
significantly extended ex vivo lifespan, delayed replicative
senescence, and enhanced function. While the ability to
expand OEC numbers prior to autologous or allogeneic
therapy remains a useful property, their replicative senes-
cence and associated impairment of vasorepair needs to be
considered. This study also suggests that modulation of
the senescence-associated secretory phenotype could be
used to optimize OEC therapy. STEM CELLS 2013;31:1657–
1668
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
Harnessing the vasoreparative potential of endothelial progen-
itor cells (EPCs) has emerged as a viable therapeutic option
for ischemic diseases such as myocardial infarction [1], pe-
ripheral arterial disease [2], and ischemic retinopathies [3]. In
addition, generation of new blood vessels is a critical step in
tissue engineering strategies, and EPCs are currently being
considered for enhancing wound repair, osteogenesis, and de-
velopment of 3D-vascularized liver organoids. The therapeutic
potential of EPCs underpins the necessity to develop an effi-
cient, clinically relevant EPC isolation and ex vivo expansion
protocol for subsequent use in therapeutic angiogenesis and
tissue engineering.
A frequently overlooked hurdle in adult stem cell thera-
pies is the generation of sufficient cell numbers required
for delivery into patients [4] and viability of an EPC-based
cytotherapy relies on safe and efficient expansion of cell num-
bers ex vivo from tens to millions. Large-scale expansion of
adult stem cells is often limited by the exhaustion of their
replicative potential. Although many reports highlight the
remarkable proliferative capacity of a distinct EPC subtype
known as outgrowth endothelial cells (OECs) or endothelial
colony forming cells (ECFCs) [5, 6], the implications for their
long-term expansion remain largely unknown and detailed
molecular and functional evaluation is required.
Cellular senescence has been reported to occur during ex
vivo expansion of adult stem cells [7]. Senescence of mesen-
chymal stem cells and hematopoietic stem cells (HSCs) is
associated with significant changes in their differentiation
potential and gene expression profile [8, 9] which impact on
their therapeutic efficacy. In this study, we have investigated
the ex vivo growth dynamics and senescence program of this
well-defined and characterized EPC subpopulation commonly
known as OECs [10, 11] or ECFCs [5, 6]. We show that
OECs can be successfully expanded ex vivo, although these
cells ultimately undergo senescence upon exhaustion of their
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replicative potential. In addition, we demonstrate that in com-
parison to presenescent (early-passage) OECs, senescent
OECs are dysfunctional, and by analysis of their transcrip-
tome, proteome, and secretome, we have identified molecular
players during OEC senescence. interleukin 8 (IL8) was rec-
ognized as a critical component and here we report that by
knocking down expression of this cytokine in OECs, the
establishment of cellular senescence was significantly delayed.
Through better understanding of the molecular pathways that
control OEC senescence, we may ultimately be able to over-
come the major challenge of efficiently expanding cell num-
bers without diminishing functionality.
MATERIALS AND METHODS
Cell Isolation and Culture
This study was approved by the Office for Research Ethics
Committees Northern Ireland. OECs were isolated from
human peripheral (PB) and umbilical cord blood (CB) as pre-
viously described [11]. Human PB was obtained with full eth-
ical approval from healthy, nonsmoking volunteers aged 22–
35 years who were not receiving any medication. Umbilical
CB was obtained with full ethical approval from full-term
neonates. Operational definition for early-passage OECs in
this study was cells that were in their exponential phase of
the growth curve (between passage 4 and 6 for PB-derived
OECs [PB-OECs] and between passage 8 and 12 for umbili-
cal CB-derived OECs [CB-OECs]), while late-passage OECs
were cells that have reached their Hayflick limit. The CASY
cell counter-analyzer (Roche, Germany, http://www.roche-
applied-science.com) was used for cell counts and cellular
size assessment.
Cytochemical Staining
Senescence-associated b-galactosidase (SA-b-Gal), bromo-
deoxyuridine (BrdU) incorporation, and cH2AX inmunocyto-
chemistry assays were performed using standard protocols
which are outlined in Supporting Information.
Cell Cycle Analysis
Detailed in Supporting Information.
Telomere Length and Telomerase Activity Assays
The telomere PNA kit/fluorescein isothiocyanate (FITC) for
flow cytometry (DAKO, http://www.dako.com) was used to
measure telomere lengths according to manufacturer’s proto-
col. For measurement of telomerase activity, the quantitative
telomerase detection kit (US Biomax, http://www.biomax.us)
was used in accordance with manufacturer’s guidelines.
RNA Extraction and Microarray Analysis
Total RNA was extracted using an RNAqueous kit (Ambion
Life Technologies, http://www.ambion.com), and 1 lg of
RNA from each cell sample was labeled and hybridized to an
Illumina WG-6 v3.0 Expression Beadchip (Illumina, http://
www.illumina.com). Samples analyzed in the array were three
PB-OEC biological replicates of early and late passages. Gene
expression data obtained from Illumina Beadstudio was nor-
malized by using an ‘‘R’’ bioconductor with a ‘‘lumi’’ pack-
age. Data were processed and analyzed using various bioin-
formatics software packages detailed in Supporting
Information. Microarray data are available at the ARRAYEX-
PRESS database with accession number E-MTAB-1388.
Real-Time Reverse-Transcription Polymerase Chain
Reaction
Detailed in Supporting Information.
Human Angiogenesis and Cytokine Protein Arrays
OEC protein lysates and conditioned media were analyzed by
using the Proteome Profiler human angiogenesis and cytokine
arrays (R&D Systems, Minneapolis, MN, http://www.rndsys-
tems.com) in accordance with manufacturer guidelines. Spots
were detected by using chemiluminescence, and densitometry
was quantified using ImageJ software.
IL8 ELISA
IL8 levels were assessed by ELISA using Human IL-8 ELISA
MAX (Biolegend, http://www.biolegend.com) according to the
manufacturer’s instructions.
In Vitro Cell Functional Assays
Tubulogenesis, migration, and clonogenic assays were per-
formed following standard protocols detailed in Supporting
Information.
Murine Model of Retinal Ischemia
C57BL/6 mice were purchased from Harlan Laboratories,
U.K. All experiments were performed in compliance with the
Association for Research in Vision and Ophthalmology state-
ment for the use of animals in Ophthalmic and Vision
Research and UK Home Office regulations. Ischemic retinop-
athy was induced in C57BL/6 mice by using the previously
described oxygen-induced retinopathy model (OIR) [11] and
summarized in Supporting Information.
IL8 Small Hairpin RNA (shRNA) Lentiviral
Transduction
IL8 gene expression knockdown was carried out using the
Dharmacon SMARTvector 2.0 system (Thermo Fisher Scien-
tific, http://www.thermofisher.com) targeting IL8, according to
the manufacturer’s protocol. SMARTvector 2.0 Non-targeting
Control Particles were used alongside the silencing constructs
targeting IL8 for all downstream experiments.
Protein Extraction and Western Blotting
Detailed in Supporting Information.
Statistical Analysis
All data are expressed as mean 6 SEM. Statistical signifi-
cance of differences between groups was determined by using
one-way ANOVA with the Student-Newman-Keuls post-test
with Prism5 Graphpad software.
RESULTS
OECs Have a Finite Replicative Lifespan In Vitro
Human OECs were isolated following well-established proto-
cols [5, 11]. OECs were characterized as highly proliferative
cells that grow as a monolayer with cobblestone-like morphol-
ogy (Fig. 1A), form adherens junctions through cadherin pro-
teins (Fig. 1B), and express endothelial markers VEGFR2
(Fig. 1C) and caveolin 1 (Fig. 1D). Furthermore, immunophe-
notypic analysis by flow cytometry (Fig. 1E) indicates this
EPC subpopulation does not contain any hematopoietic cells
(negative for CD45 and CD14), it is mainly composed of cells
of endothelial lineage (99% positivity for CD31, CD105,
and CD146), and also expresses the progenitor cell marker
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CD34 (albeit with variation according to passage number).
Human OECs have been previously characterized at the tran-
scriptome, flow cytometric, and ultrastructure levels [10, 11].
To evaluate the growth kinetics and replicative potential of
OECs, growth curves were generated following strict record-
ing of cell numbers during serial passage of adherent cultures
(Fig. 2A). As expected for progenitors, all OEC clones
showed considerably enhanced replicative potential when
compared to human aortic endothelial cells and human dermal
microvascular endothelial cells (HDMECs), which were used
as differentiated mature counterparts. CB-OECs exhibited
greater proliferative capacity than PB-OECs with the former
demonstrating, on average, 60 population doublings in 70
days, compared with PB-OECs which reached their Hayflick
limit at 27 population doublings in 40 days. By contrast,
mature endothelial cells displayed only 10 population dou-
blings in 30 days.
Morphological assessment indicated a significant increase
in cellular size during ex vivo expansion (Fig. 2B). Late-pas-
sage cells showed a fourfold enlargement of the cellular sur-
face area (Supporting Information Fig. S1A) and an increase
in cellular diameter occurred in unison with population dou-
bling time (Fig. 2C). This physical enlargement of late-pas-
sage cells was even evident after monolayer trypsinization,
with a significant increase in volume observed at the single
cell level (p < .001) (Fig. 2D).
The percentage of cells retaining the ability to synthesize
DNA and incorporate BrdU (Fig. 2E) decreased significantly
from 13% to < 2% (p < .001) (Fig. 2F). In addition, DNA con-
tent analysis using flow cytometry indicated that most late-pas-
sage OECs were arrested in the G1 phase of the cell cycle (Fig.
2G). When compared to early-passage OECs, late-passage
OECs showed a significant decrease in the percentage of cells
at S and G2/M (p < .001) (Fig. 2H). Collectively, these data
demonstrate that although OECs can be efficiently expanded in
vitro, their replicative potential is limited. After long-term
expansion of OECs, cell numbers reach a plateau exemplified
by the Hayflick limit where most cells are growth-arrested in
G1 and have acquired an enlarged flattened morphology.
OEC Growth Arrest Induced by Continuous Culture
Ex Vivo Is Replicative Senescence
Since cellular growth arrest can be defined as quiescence or
senescence, our next aim was to identify which process was
contributing to OEC growth arrest ex vivo. Contrary to quies-
cence, senescence is an irreversible state and cells typically
show a complete loss of proliferative potential. Despite appro-
priate growth stimuli, such as availability of nutrients and
space, OEC proliferation eventually became completely halted
(Fig. 1A), which was suggestive of a senescence process. To
confirm this, we measured SA-b-Gal activity at pH6, which is
currently the most commonly used biomarker for senescence.
Late-passage OECs showed a marked increase in SA-b-Gal
activity when compared to early-passage counterparts (Fig.
3A). Quantification indicated a significant increase in the per-
centage of cells that were positive for SA-b-Gal; 3% in early-
passages increasing to 60% in late-passages (Fig. 3B). SA-b-
Gal activity is associated with expansion of the lysosomal
mass [12]; therefore a lysotracker probe was used. Consistent
with SA-b-Gal data, there was a significant fourfold increase
in the lysosomal mass per cell when comparing early- to late-
passage OECs (Supporting Information Fig. S1B, S1C). DNA
damage is a cardinal feature of cellular senescence, and the
presence of the established DNA damage marker c-H2AX
was evaluated during the replicative lifespan of OECs
(Fig. 3C). A significantly higher percentage of OECs positive
for c-H2AX was observed in the late-passage group when
compared to early-passage cells (p < .001) (Fig. 3D).
Senescence is associated with major changes in gene
expression therefore we performed transcriptome analysis.
Total RNA was extracted from early- and late-passages for
the same OEC clone, and three biological replicates were
used for transcriptome analysis using the Illumina WG-6 v3.0
expression beadchips to assay more than 48,000 transcripts.
Statistical assessment using National Institute on Aging array
analysis distinguished a significant differential gene expres-
sion when comparing early- and late-passages (Fig. 3E).
Overall, 782 transcripts were found to be significantly upregu-
lated in early-passage OECs, while 654 transcripts were sig-
nificantly upregulated in late-passage OECs. Differences in
gene signatures were consistent among three different
Figure 1. Characterization of endothelial progenitor cells as the
outgrowth endothelial cell (OEC) population. (A): OECs grow in cul-
ture as a cobblestone-shaped cell monolayer. Scale bar ¼ 100 lm.
(B): Immunofluorescence staining for Vimentin (red) and cadherin
(green). Nuclei are counterstained with 40,6-diamidino-2-phenylindole
(DAPI) (blue). (C): VEGFR2 expression is shown in green. (D): Cav-
eolin 1 expression in OECs is shown in green. Scale bars in (B–D) ¼
50 lm. (E): Immunophenotypic characterization of OECs by flow
cytometry. Cell surface antibodies are shown in red histograms, re-
spective isotype controls in blue histograms. The percentage of posi-
tive cells appears in the top right of each panel.
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biological replicates, as shown in heatmaps for the most
altered genes (Fig. 3F). Quantitative reverse transcriptase po-
lymerase chain reaction (qRT-PCR) was used to validate
microarray results and showed comparable changes (Fig. 3G).
In order to gain an insight into the biological meaning behind
this long list of genes, gene ontology analysis for biological
processes was performed using the functional genomics tool
FunNet. This highlighted that while gene ontologies for tran-
scripts significantly upregulated in early-passage OECs were
associated with cell cycle, mitosis, and DNA replication; gene
Figure 2. OECs exhibit a finite replicative lifespan in vitro. (A): Growth curves for ex vivo expanded cord blood-derived OECs (green), pe-
ripheral blood-derived OECs (red), human aortic endothelial cells (HAECs) and human dermal microvascular endothelial cells (HDMECs) in
blue. (B): Representative phase-contrast micrographs of cultured OECs at different stages during their in vitro lifespan. Scale bars ¼ 100 lm.
(C): Concomitant increase in doubling time and cell diameter with cellular passage. (D): Comparison of cell volume between early-passage and
late-passage OECs. Bottom panel shows representative phase-contrast micrographs of OECs in the hemocytometer chamber. (E): Immunofluores-
cence staining for BrdU shown in green, nuclei are counterstained in red with PI. Scale bars ¼ 100 lm. (F): Quantification and statistical analysis
comparing BrdU incorporation in early- and late-passage OECs (n ¼ 4). (G): Cell cycle analysis using flow cytometry and PI demonstrates
growth arrest at the G1 phase of the cell cycle in late-passage OECs. (H): Quantification of cell cycle analysis comparing early and late-passage
OECs. Late-passage OECs had significantly fewer cells in the S and G2/M phase, while exhibiting a significant increase in the G1 phase (n ¼ 3).
The error bars indicate standard error; ***, p < .001. Abbreviations: BrdU, bromodeoxyuridine; CB, cord blood; HAEC, human aortic endothelial
cell; HDMEC, human dermal microvascular endothelial cells; OEC, outgrowth endothelial cell; PB, peripheral blood; PI, propidium iodide.
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ontologies associated with late-passage OECs were proteoly-
sis, cell adhesion, and lysosome organization (Fig. 3H). Simi-
lar results were obtained when data were processed using
visANT software (Supporting Information Fig. S2). Further
analysis using Ingenuity software identified molecular path-
ways associated with OEC senescence which included p53,
transforming growth factor (TGF), tumor necrosis factor
(TNF), interferon (IFN), and inflammatory cytokines IL8,
IL1A, and IL6 (Fig. 3I). To examine the possibility of endo-
thelial differentiation during in vitro expansion of progenitors,
the transcriptome was assessed for variations in gene expres-
sion of endothelial differentiation and progenitor markers.
Interestingly, we found that while progenitor markers expres-
sion such as SOX18 and CD34 decreased in late passages, en-
dothelial differentiation markers such as CDH5 and ESM1
increased in late passages (Supporting Information Fig. S3A).
Consistent with these findings, flow cytometry analysis
revealed that CD34 expression significantly decreased from
72% in early passages to 13% in late passages. Similarly, c-
kit expression significantly decreased from 23% to 2%
between early and late passages, respectively (Supporting In-
formation Fig. S3B). Together these findings, at the transcrip-
tome and protein expression level, suggest that senescence
triggered by in vitro expansion is coupled to endothelial dif-
ferentiation. Nevertheless, results from long-term cell number
amplification in vitro indicate that the high proliferative
potential of OECs is a useful feature that allows them to be
clearly distinguished from mature endothelial cells (Fig. 2A).
Classic cellular senescence is driven by tumor suppressor
pathways p53 and pRb, therefore expression of these proteins
was investigated (Fig. 3J). While there was no difference in
the expression of total p53, a clear increase in phosphorylated
p53 was observed in late-passage OECs. In addition, p21 and
pRb were consistently upregulated in late-passage OECs,
while cyclin A was only found in early-passage OECs.
Having established that late-passage OECs are senescent,
we investigated if the OEC senescence program during ex vivo
expansion was associated with telomere erosion as a result of
continuous cell division in culture. Flow cytometry and fluores-
cence in situ hybridization (FISH) were used to measure the av-
erage length of telomeres from the same clones at different pas-
sages. Dot plots illustrated fluorescence measurements of cells
incubated with FITC-conjugated telomere-specific peptide
nucleic acid (PNA) probes were compared to cells incubated
with the negative controls. Overlap of populations was found
only in senescent cells (Fig. 4A) indicating that these OECs had
shorter telomeres. Further quantification by evaluating mean
fluorescence intensities in histograms (Fig. 4B) highlighted sig-
nificant telomere shortening in senescent OECs when compared
to early-passage OECs (p < .001) (Fig. 4C). Telomerase, shown
to be highly expressed in cancer and stem cells, extend telo-
meres after each round of cell division. We used the telomere
repeat amplification protocol (TRAP) assay to detect telomer-
ase activity in early-passage and senescent OECs. The myeloid
cell line U937 was used as a control for high telomerase activity
while the primary isolates of HDMECs served as control for
low telomerase activity. In agreement with previous results,
decreased telomerase activity was observed in senescent OECs
from all the clones (Fig. 4D) thereby providing further evidence
that OECs undergo replicative senescence during expansion.
Cellular Senescence Limits the Regenerative
Potential of OECs
While there is evidence linking cellular senescence to both
stem cell and endothelial cell dysfunction, there is remarkably
little known about how senescence affects OEC functionality.
Figure 3. OEC growth arrest induced by ex vivo expansion is a
result of cellular senescence. (A): Representative images for early-
and late-passage OECs stained for SA-b-Gal shown in blue. Scale
bars ¼ 100 lm. (B): Statistical analysis comparing percentages of
SA-b-Gal positive cells in early-passage versus late-passage OECs (n
¼ 4). (C): Representative immunofluorescence staining for DNA
damage marker c-H2AX in green. Nuclei are counterstained in red
with PI. Scale bars ¼ 100 lm. (D): Statistical analysis comparing per-
centages of c-H2AX positive cells in early-passage versus late-pas-
sage OECs (n ¼ 4). (E): Dot plot for genome-wide transcriptome
analysis using National Institute on Aging array with false discovery
rate (FDR) ¼ 0.05 to compare early-passage with late-passage OECs.
782 transcripts were significantly upregulated in early-passage OECs
(shown as red dots), while 654 transcripts were significantly upregu-
lated in late-passage OECs (green dots). (F): Heat map for the top 30
upregulated and downregulated transcripts demonstrates a consistent
gene expression change among paired biological replicates (n ¼ 3).
(G): Real time quantitative reverse transcriptase polymerase chain
reaction for SOX18, HMGB2, CCNB2, IFI27, IL8, and CXCL6 serve
to show consistent alterations between early and late-passage OECs
and validate gene microarray results. (H): GO assessment using the
functional genomics tool FunNET. (I): Molecular pathway network
analysis using Ingenuity software for assessment of transcripts upreg-
ulated in late-passage OECs. (J): Western Blotting to evaluate
expression of phospho-p53, p21, pRb, and cyclin A in early- and
late-passage OECs. The error bars indicate SE; ***, p < .001.
Abbreviations: EP, early passage; GO, gene ontology; IL, interleukin;
LP, late passage; OEC, outgrowth endothelial cell; PI, propidium
Iodide; SA-b-Gal, senescence-associated b galactosidase activity.
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Thus, we examined whether replicative senescence impairs
functional properties of OECs. First, we used a scratch wound
assay to compare migratory capacities of early-passage and
senescent OECs. Eight hours after creating the wound, early-
passage OECs almost closed the gap while senescent OECs
show much reduced capacity (Fig. 5A). Quantification of
migrated areas corroborated this qualitative data (p < .001)
(Fig. 5B). Second, the Oris cell migration assay was used. In
agreement with the scratch wound assay, we found impair-
ment in the migratory capacity of senescent OECs (Fig. 5C),
which was significantly lower than that of early-passage
OECs (p < .001) (Fig. 5D). To test tubulogenic potential, a
Matrigel-based 3D angiogenesis model was performed
(Fig. 5E). After 72 hours, it was evident that in vitro tube
forming capacity was significantly impaired in senescent
OECs (p < .001) (Fig. 5F).
The impact of OEC senescence on their vasoreparative
(therapeutic) potential was investigated in vivo using the OIR
model. OIR provides a consistent and reliable preclinical sys-
tem to test the therapeutic benefit of a cytotherapy by objec-
tively assessing vascular repair in the ischemic retina. Mouse
pups consistently developed vaso-obliteration of the central
retina at P12 (Fig. 5G). At P13, mice were divided into three
experimental groups (n ¼ 6 animals per group) for the deliv-
ery of equal numbers of early-passage OECs, senescent
OECs, or vehicle. Cells were prelabeled with fluorescent
Qdots and delivered via intravitreal injection. Retinas were
sampled at 72 hours and vascular areas were evaluated by
Isolectin staining (Fig. 5G). Injection of both early- and late-
passage OECs resulted in a significant reduction of the avas-
cular area (p < .001). Although senescent OECs were still
beneficial, they were less vasoreparative than their normal
counterparts (Fig. 5H). Despite the observed reduction in reti-
nal ischemia, it was apparent that most senescent OECs did
not integrate into the resident vasculature as efficiently as
the early-passage OECs. Further quantification of preretinal
pathological neovascularization showed that only the early-
passage OECs significantly decreased the amount of neovas-
cular tufts (p < .001) (Fig. 5I). Quantification of neovascular
areas confirmed that there was no difference among the
groups treated with senescent OECs and vehicle (Fig. 5I).
These findings indicate that replicative senescence not only
affects the proliferative potential of OECs but also their
migratory and tubulogenic capacities. Most importantly, when
used as a cytotherapy for vascular repair, senescent OECs do
not perform as well as their presenescent counterparts.
Senescence Program of OECs Has a Major Inflam-
matory Component
Key factors involved in OEC senescence were identified using
transcriptomic analysis. Ingenuity Pathway software deter-
mined ‘‘Inflammatory Response’’ as the top BioFunction in
senescent OECs. Alongside this, the resultant gene network
established for transcripts upregulated in senescence included
many inflammatory cytokines, such as IL8, IL1A, IL32,
IL6ST, and CXCL1 (Supporting Information Fig. S4A). This
was confirmed using REVIGO software which highlighted
‘‘Regulation of cytokine production’’ in the center of the
semantic space for senescent OEC transcripts (Supporting In-
formation Fig. S4B), suggesting an important role for inflam-
matory cytokines in modulation of senescence-upregulated
genes. Ingenuity software also recognized STAT3, STAT2,
and TP53 as transcription factors associated to senescent
OECs upregulated genes. This was confirmed by Genomatix
software, which assessed promoters of senescence-upregulated
genes, indicating STAT1, STAT2, STAT3, TP53, and NFjB
Figure 4. Telomere shortening as a hallmark of replicative senescence
in OECs. (A): Telomere length was determined by flow cytometry using
fluorescence in situ hybridization and a fluorescein-conjugated peptide
nucleic acid probe. Representative dot plots show two distinct cell popu-
lations which have been incubated with and without an fluorescein iso-
thiocyanate (FITC)-conjugated peptide nucleic acid probe specific for
telomere repeats. These are shown as gray and black dots, respectively.
Note that overlap only exists in senescent cells. (B): Representative fluo-
rescence intensity histograms show differences in mean fluorescence
intensities between telomere probes and control probes (gray filled histo-
grams and white histograms, respectively). Note the larger distance
between peaks in the early-passage OEC group compared to the late-pas-
sage group. (C): Quantification of telomere length by normalizing distan-
ces between mean fluorescent intensities to arbitrary units (A.U.).
Statistical analysis to compare early-passage and senescent OECs. (D):
Telomerase activity was assessed using the telomere repeat amplification
protocol (TRAP) assay for pairs of OEC clones (n ¼ 3). Note that there
is a significant decrease in telomerase activity when comparing senescent
OECs to their early-passage counterparts. The U937 cell line was used as
a positive control for high telomerase activity, and HDMEC provided an
appropriate control for low telomerase activity. The error bars indicate
SEM. ***, p < .001. Abbreviations: HDMEC, human dermal microvas-
cular endothelial cells; OEC, outgrowth endothelial cell.
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as relevant transcription factors. All this in silico analysis of
transcriptomic data, using a diverse range of bioinformatics
software, indicated a strong link between OEC replicative se-
nescence and inflammation-related pathways. Therefore, we
next compared gene expression of inflammatory cytokines by
qRT-PCR in early-passage versus senescent OECs. Although
no difference was found in gene expression of the NFjB
components rela and ikkb, there was a significant upregulation
of IL8, IL1B, and IL1A (Supporting Information Fig. S5). To
confirm these results at the protein level, an angiogenesis pro-
teome profiler was used. Proteins with increased expression in
senescent OECs included IL8 and IL1B (Fig. 6A).
Recently, the senescence-associated secretory phenotype
(SASP) [13] or senescence messaging secretome [14] has been
included as a hallmark of cellular senescence. This information
prompted the characterization of the secretome in senescent
OECs. A cytokine proteome profiler was used to identify and
quantify proteins present in the conditioned media of early-pas-
sage and senescent OECs. The most abundant protein in the
senescent OEC secretome was IL8, which was expressed to a
similar level as positive controls (Fig. 6B). Densitometric anal-
ysis confirmed a significant fivefold increase in IL8 when con-
ditioned media from senescent OECs was compared to condi-
tioned media of early-passage OECs (p < .001) (Fig. 6C).
Other proteins shown to increase in the secretome during senes-
cence were CXCL1, sICAM-1, and IL6; proteins that were
present at similar levels were MIF and CCL2; while PAI-1
expression decreased in senescent secretomes (Supporting In-
formation Fig. S6). Quantitative ELISA corroborated a signifi-
cant increase in the IL8 levels secreted per cell when comparing
early-passage to senescent OECs (p < .001) (Fig. 6D). Limulus
amebocyte lysate (LAL) endotoxin testing confirmed that cell
culture conditions at both early and late-passages were free of
bacterial endotoxins or lipopolysaccharide (LPS) (Supporting
Information Fig. S7).
These results at transcriptome, proteome, and secretome
levels indicate that there is a clear association between inflam-
matory cytokines and OEC replicative senescence. This sug-
gests a possible role for some of these cytokines in the induc-
tion, establishment, or reinforcement of OEC senescence.
IL8 Depletion Delays Replicative Senescence
in Cultured OECs
A network of inflammatory cytokines was found to be signifi-
cantly upregulated in senescent OECs and it was therefore im-
portant to establish if these might play a role in the senes-
cence program of these cells. Our investigations focused on
IL8 since it was consistently among the most differentially
expressed mRNA and the most highly expressed cytokine in
the secretome of senescent OECs. The SMARTvector 2.0 len-
tiviral shRNA technology was used to knockdown IL8 expres-
sion in OECs with approximately 93% transduction efficiency
after Puromycin selection (Supporting Information Fig. S8A,
S8B). qRT-PCR confirmed a significant decrease in IL8
mRNA when shRNA-IL8 transduced cells were compared to
Figure 5.
Figure 5. Replicative cellular senescence limits OEC regenerative
potential by impairing vasoreparative properties. (A): Representative
phase-contrast micrographs for the scratch wound assay on early-pas-
sage and senescent OECs. Wound edge delineated with yellow dots.
(B): Quantification of migrated areas using NIS elements software (n
¼ 10). Note significant impaired migration in senescent OECs. (C):
Oris Cell Migration Assay with OECs prestained using the vital dye
calcein red. The central area where cells migrated is outlined in yel-
low. (D): Quantitative analysis of migrated areas (n ¼ 12). Note sig-
nificantly smaller migrated areas in the senescent OEC group. (E):
The tube-forming capacity of OECs was assessed using the 3D-angio-
genesis model. Representative images of OECs embedded in Matrigel
7 days after starting the assay. Calcein staining in red. (F): Quantifi-
cation of tube length per field of vision (n ¼ 4) shows significantly
decreased tube forming capacity in senescent OECs. (G): The oxygen
induced retinopathy model was used to determine the therapeutic
potential of OEC cytotherapy. Murine retinal flat mounts were stained
using isolectin (green) to identify retinal vasculature and multiple
images per retina with magnification 10 were taken and stitched
together using NIS elements software. The central avascular area is
shown in black and delineated with a yellow line. Images at postnatal
day 12 (P12) shows the ischemic state of retinas at the point of OEC
delivery by intravitreal injection. All other images were taken 72
hours after cell or vehicle delivery. (H): Quantification of the avascu-
lar area of retinas 72 hours after intravitreal injection with either vehi-
cle, EP-OECs, or LP-OECs (n ¼ 6). Note senescent OECs
significantly decrease avascular areas but with less efficiency than
early-passage counterparts. (I): Quantification of the pathological pre-
retinal neovascularization 72 hours after intravitreal injection of
OECs (n ¼ 6). In contrast to early-passage OECs, note that senescent
cells fail to significantly decrease pathological neovascularization.
The error bars indicate SEM. *, p < .05; ***, p < .001; ns, not sig-
nificant. Scale bars (A, C, E) ¼ 250 lm. Abbreviations: EP, early
passage; LP, late passage; OEC, outgrowth endothelial cell.
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shRNA-controls (Supporting Information Fig. S8C). We next
explored the presence of cytokines in the secretome of OECs
transduced with shRNA-IL8 and shRNA-control. As expected,
there was a significant decrease of IL8 expression in the
shRNA-IL8 group to 16% of the IL8 levels found in the
shRNA-control group (Fig. 7A). Interestingly, we found that
depletion of IL8 concomitantly lead to a significant decrease
in the expression of MCP-1 and IL6, while there were no
changes in the expression of PAI-1, MIF, and CXCL1 (Sup-
porting Information Fig. S9). Further quantification of condi-
tioned media by ELISA indicated that shRNA-control and
nontransduced OECs have similar IL8 levels, while there was
a significant decrease from 1,208 pg/mL in shRNA-control
OECs to 101 pg/mL in shRNA-IL8-transfected OECs (p <
.001) (Fig. 7B).
In order to determine the potential regulatory role of IL8
in the OEC senescence program, growth curves for shRNA-
IL8 and respective shRNA-control were generated. IL8 deple-
tion markedly delayed OEC senescence during ex vivo expan-
sion, as shown by more than twofold increase in accumulated
population doublings and protracted exponential phase of the
growth curve (Fig. 7C). Clonogenic assays corroborated
results from growth curves, larger sized and greater numbers
of single cell-derived colonies occurred in the shRNA-IL8
group (p < .001) (Fig. 7D). Analysis of SA-b-Gal revealed a
significant decrease in the number of OECs positive for this
senescence biomarker when IL8 was depleted (p < .001)
(Fig. 7E). This is consistent with a marked decrease in DNA
damage in IL8-depleted OECs as shown by immunocyto-
chemistry for 53BP1 nuclear foci (Supporting Information
Fig. S10).
To assess the impact of IL8 on senescence-related loss
of functionality, Matrigel-based tubulogenesis assays were
used. shRNA-mediated depletion of IL8 restored tube form-
ing potential as indicated by the significant increase in the
number of branching points when shRNA-IL8 OECs were
compared to shRNA-control OECs at the same passage (p
< .001) (Fig. 7F). In agreement with this, the migratory
capacity of late-passage OECs was significantly enhanced
(p < .001) when IL8 was depleted (Fig. 7G). These results
provide evidence of a role for IL8 during OEC replicative
senescence since attenuating expression of this cytokine
not only delayed senescence but also increased prolifera-
tion rate, extended in vitro lifespan, and enhanced
functionality.
We also investigated the functional role of shRNA-IL8
OECs in an in vivo model of ischemic retinopathy. Interest-
ingly, these transplanted, virally modified OECs induced a
marked inflammatory cell infiltration response when compared
to vehicle-injected controls in the contra-lateral retina (Support-
ing Information Fig. S11A). Myeloid cells accumulated prefer-
entially around endothelial tubes formed by shRNA-IL8 OECs
(Supporting Information Fig. S11B). This finding underscores
the importance of establishing the immunogenic potential of ge-
netically modified OECs before their usage in cell therapies and
is currently being investigated by our group.
As IL8 has been previously described as a mediator of
angiogenesis, its effects on the OEC angiogenic program
were dissected and studied at three distinct cellular passages
prior to the onset of senescence. OEC treatment with IL8
varied from 1 to 100 ng/mL and proliferative potential
decreased with cellular passage (Supporting Information Fig.
S12A). However, IL8 did not increase colony-forming
capacity in any group but significantly decreased prolifera-
tive potential when early-passage OECs were exposed to
higher IL8 concentrations (p < .05) (Supporting Information
Fig. S12B). Results from OEC migration studies agreed with
OEC colony formation data. Late passage OEC migration
rate was lower than early passage counterparts (Supporting
Information Fig. S12C), and there was only a significant
decrease in migration areas when early-passage OECs were
exposed to high IL8 doses (p < .01) (Supporting Information
Fig. S12D). In other passages, there was no significant effect
when OECs were exposed to IL8. Assessment of OEC tube
formation consistently indicated a clear decrease in tube
forming capacity with cellular passage (Supporting Informa-
tion Fig. S12E). Interestingly, while late-passage OECs do
not respond to IL8 (Supporting Information Fig. S12F), we
found a significant increase in tube length when early-
and mid-passage OECs were exposed to lower doses of IL8
(p < .001). Exposure of OECs to exogenous recombinant
human IL8 for 5 days did not affect their intrinsic senes-
cence program (Supporting Information Fig. S12G, S12H).
These findings indicate that a proangiogenic effect for IL8 is
only found in early and mid-passage OECs and with low
IL8 concentrations (1 ng/ml) as demonstrated by the
tube formation assay. Late-passage OECs are clearly
nonresponsive to IL8 pro-angiogenic effects.
Figure 6. Inflammatory component identified in OEC senescence
program. (A): Protein lysates from early-passage and senescent OECs
were assessed using the human angiogenesis proteome profiler. Senes-
cent OECs showed increased expression of many proteins (high-
lighted by black box). Positive controls are included in the top
corners and bottom left corner and negative controls in the bottom
right corner. (B): Human cytokine proteome profiler for evaluation of
conditioned media from early-passage and senescent OECs. Note
higher IL8 secretion from senescent cells while no changes are
observed in MIF and positive controls. (C): Quantification of cytokine
array by densitometry using ImageJ software (n ¼ 4). (D): ELISA
quantification of IL8 levels in conditioned media from early-passage
and senescent OECs (n ¼ 6) shows higher levels in senescent cells.
The error bars indicate SEM. ***, p < .001. Abbreviations: EP, early
passage; GM-CSF, granulocyte macrophage colony stimulating factor;
IL, interleukin; OEC, outgrowth endothelial cell; MCP, monocyte
chemotactic protein; MIF, macrophage migration inhibitory factor;
TIMP, tissue inhibitor of metalloproteinase.
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DISCUSSION
In this study, we provide evidence demonstrating the mark-
edly enhanced replicative potential of OECs in comparison to
mature endothelial cells. This characteristic favors the isola-
tion of OECs and their possible use for cell therapy, since
large numbers of cells are typically required and are essential
for autologous/ allogeneic stratagems. A porcine model of
acute myocardial infarction recently showed that efficient neo-
vascularization of an individual ischemic heart required a
minimum delivery of 30 million OECs [15], which is equiva-
lent to approximately ten 75 cm2 confluent cell culture flasks.
If we consider that a homogeneous OEC population is gener-
ally established in vitro after passage 3 with approximately
100,000 cells, then a minimum of eight population doublings
is required to amplify cell numbers for therapeutic use. Our
data shows that this is feasible for both CB- and PB-derived
OECs, as shown by their respective growth curves. However,
our observations also indicate that OECs expanded ex vivo
ultimately undergo senescence upon exhaustion of their repli-
cative potential. Critically, the current investigation has shown
that the molecular fingerprint for senescence is coupled to a
dysfunctional phenotype which underlines the importance of
evaluating the senescence program when expanding progeni-
tor cells for clinical use.
The evidence demonstrating that OECs undergo replica-
tive senescence during expansion in culture underscores their
safety when applied to human cytotherapy. Very recently, it
has been noted that senescence in culture is the most reliable
test for tumorigenicity [16], because assays using nude mice
have unacceptably low sensitivity.
Although cytotherapy for vascular repair during ischemia
using patients’ own blood/bone marrow has been shown to be
attainable [17], this autologous strategy faces significant limi-
tations: (a) considering that OEC isolation and expansion
takes at least 6 weeks, there is a narrow window of opportu-
nity for treatment of patients with acute ischemic conditions;
(b) patient’s clinical background and age can alter OEC func-
tionality and numbers, for example, it has been reported that
Figure 7. shRNA lentiviral transduction-mediated IL8 depletion delayed outgrowth endothelial cell (OEC) senescence. (A): The human cyto-
kine proteome array was used to evaluate IL8 expression by assessing conditioned media of OECs transduced with either shRNA-control or
shRNA-IL8 lentiviral constructs. Quantification of blots by densitometry (n ¼ 4) shows efficient IL8 knockdown in OECs transduced with IL8-
shRNA. (B): ELISA quantification of IL8 levels in conditioned media of shRNA-control and shRNA-IL8 transduced OECs, compared to same
passage nontransduced OECs (n ¼ 3). (C): Growth curves for shRNA-control and shRNA-IL8 OECs shown in blue and red, respectively. (D):
Clonogenic assay comparing colony formation potential of shRNA-control and shRNA-IL8 OECs (n ¼ 6). Bottom panel shows representative
image of cells stained with crystal violet to identify and count colonies. (E): SA-b-Gal assay 1 month after lentiviral transduction. Representative
images showing higher expression (blue) in shRNA-control OECs. Scale bars ¼ 100 lm. Quantification demonstrates significantly fewer cells
positive for SA-b-Gal in the shRNA-IL8 group (n ¼ 8). (F): Representative images of tube-like structures formed in the Matrigel 3D angiogene-
sis model. Cells stained in green with vital dye calcein. Quantification of number of branch points formed per field of vision (n ¼ 12). Scale bars
¼ 250 lm. (G): Quantitative analysis of migrated areas using the scratch wound assay shows impaired migration potential in shRNA-control
OECs (blue) when compared to shRNA-IL8 OECs (red) (n ¼ 12). The error bars indicate SEM. ***, p < .001; ns, not significant. Abbreviations:
IL, interleukin; SA-b-gal, SA-senescence-associated b galactosidase; shRNA, small hairpin RNA.
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diabetes reduces the frequency of EPCs circulating in blood
[18], and that they exhibit premature senescence [19, 20]
thereby limiting cell numbers for therapy; (c) isolation effi-
ciency for OECs from PB varies depending on the donor and
the amount of blood. In our hands, starting with 40 mL of ve-
nous blood, isolation efficiency for OECs is around 30%, so
currently it is not possible to isolate EPCs from every patient.
An attractive alternative to PB-OEC-based autologous thera-
pies is the use of umbilical CB-derived OECs for allogeneic
therapies. Umbilical CB has the advantage of being readily
available, CB-OEC isolation efficiency is greater than 90%,
and our evidence shows that they can be expanded more rap-
idly than PB-OECs. Moreover, we have previously reported
that CB-OECs can be frozen and stored in cryobanks without
alterations to their growth potential, phenotype, and karyotype
[11]. The immunocompatibility issue can be addressed by cre-
ating cell banks with detailed characterization of human leu-
kocyte antigen (HLA) haplotypes to match population require-
ments. This methodology is currently being applied to stem
cell banking of human embryonic stem cells in China [21]
and human iPS cells in Japan [22]. Another approach fre-
quently used in clinical trials for EPC isolation is the positive
selection of CD34-expressing cells from PB or bone marrow
by using a cell sorting approach. These CD34þ cells,
although shown to be beneficial in promoting revasculariza-
tion of ischemic hearts [17], contain only a fraction of
‘‘EPCs’’ as they are mainly composed of HSCs and mature
endothelial cells. The search for a reliable marker to identify
EPCs has proven extremely difficult and, to-date, cell culture
methodologies represent a viable alternative to isolate highly
homogeneous EPC populations such as OECs that can be ex
vivo expanded and further functionally characterized [6, 11].
Cell culture is commonly associated with two types of
senescence: replicative senescence and stress-induced pre-
mature senescence. While the former is directly dependent
on telomere erosion, the latter is triggered by oxidative
stress and DNA damage in the absence of significant telo-
mere shortening. Our data on OEC expansion ex vivo
shows cell proliferation with resultant telomere shortening
and characterizes OEC senescence as being mainly replica-
tive in nature. However, we cannot fully exclude the con-
tribution of exogenous ‘‘stress factors’’ intrinsic to ex vivo
culture conditions, indeed it has been reported that OECs
undergo premature senescence without telomere shortening
upon exposure to TNF-a [23]. In addition, the ‘‘chronologi-
cal age’’ of OECs at the time of isolation might also play
a role alongside the ‘‘replicative age’’ to determine the
Hayflick limit as it was demonstrated in fibroblast strains
that cells with higher replicative capacity had longer telo-
meres [24].
One important finding in this study was that senescence of
OECs, due to ex vivo expansion, significantly impairs their
functionality in vitro and diminishes their therapeutic potential
in vivo. Therefore, the nature of OEC expansion and potential
for senescence-related changes need to be taken into account
when testing OECs in clinical trials.
Another interesting finding from this study is the identifi-
cation of inflammatory cytokines as a major component of the
OEC senescence program. This is in agreement with emerging
observations highlighting that inflammatory proteins are
induced in senescent cells [25]. In fact, cellular senescence
now includes SASP as a novel hallmark [26]. Here we have
characterized the SASP in senescent OECs and identified the
cytokines IL8, IL6, IL1a, and IL1b as major components.
These data clearly demonstrate that senescence-related
changes in OECs go beyond simple growth arrest and actually
involve a dynamic process whereby cells remain metabol-
ically active and increase inflammatory cytokine production
and secretion. This phenomenon has implications for the ther-
apeutic use of OECs because these cytokines can alter tissue
microenvironment conditions and affect cell engraftment, sur-
vival, and ultimately clinical outcomes. In keeping with our
findings, it has been suggested that IL8 secreted by senescent
cells fosters cancer progression by promoting both angiogene-
sis and tumor growth [27].
Among the novel findings of this study is the identifica-
tion of IL8 as a major positive modulator of OEC senescence.
We have shown that depletion of IL8 by shRNA in OECs
leads to a significant delay in senescence, an increase in pro-
liferation rates, and restored vasoreparative function. These
data are in agreement with previous results demonstrating that
knocking down the chemokine receptor CXCR2 (IL8RB) alle-
viates replicative and oncogene-induced senescence in fibro-
blasts by diminishing the DNA damage response [28]. Fur-
thermore, a correlation between increased IL8 expression and
P16INK4A immunopositivity has been reported in growth-
arrested cells in human colorectal adenomas [25]. These find-
ings alongside ours indicate an unexpected role for secreted
inflammatory cytokines as autocrine regulators of senescence.
Although a mechanistic model has been suggested where se-
nescence-associated DNA damage triggers secretion of
inflammatory cytokines which operate as positive-feedback
loops by enhancing genes related to inflammation and cell
cycle arrest [29], further studies are warranted to dissect re-
spective molecular mechanisms. It is important to note that
IL8 depletion in OECs did not fully bypass cellular senes-
cence and this still occurred in IL8-knocked-down OECs,
albeit at a significantly delayed time point. This suggests an
enhancing and supporting role for IL8 in the senescence pro-
cess, while indicating that p53 and pRb remain the critical
components. Nevertheless, our results further advocate a
prominent and clinically relevant role for regulation of IL8
and related signaling in OEC senescence, which could be a
reasonable target to delay OEC senescence, without inducing
uncontrolled cellular growth as has been described for other
strategies targeting telomerase expression.
Identification of IL8 as one of the main components in
the OEC secretome is in agreement with other reports [30-
33]. It has been shown that OECs secrete significantly
more IL8 than human umbilical vein endothelial cells
(HUVECs) or coronary artery endothelial cells [30]. Fur-
thermore, IL8 secretion in OECs can be modulated by
PAR-1 activation [32]. In this study, we demonstrate a sig-
nificant increase of IL8 expression, production, and secre-
tion that relates to cellular passage and the ex vivo expan-
sion process of OECs. Furthermore, as IL8 levels increase
during OEC expansion and relate to senescence establish-
ment, this cytokine could potentially be used as a reliable
ageing biomarker for OECs in vitro. As OEC cell number
expansion is associated with impairment in cellular func-
tionality, there is a clear need for senescence and func-
tional screenings when OECs are expanded ex vivo. There-
fore, it is also clinically relevant to highlight that our data
shows evidence that IL8 levels in OEC conditioned media
are a consistent and reliable indicator of their passage his-
tory and relate to functionality and senescence. While early
passage OECs have IL8 levels < 50pg/ml, senescent OECs
have levels ranging from 150 to 1,200 pg/mL. These con-
centrations are very similar to the clinical parameters
described for IL8 levels in human plasma when used as a
biomarker for inflammation/infection [34].
Although we have evidence to indicate that IL8 acts as a
provascular repair factor in the ischemic retina [35], the
direct effects of IL8 on endothelial cells or OECs have not
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been clearly described. Evidence shows that while HUVECs
respond to IL8 with a significant increase in their prolifera-
tion rate, human dermal microvascular endothelial cells
failed to respond [36]. It is also important to highlight that,
in the case of HUVECs, IL8-driven proliferation requires
high IL8 concentrations (1–100 ng/mL). So far, only one
report describes the direct effect of IL8 in OECs, and results
indicate that, similar to HUVECs, very high doses of IL8
(200 ng/mL) were needed in order to induce a proangiogenic
effect [37]; in addition, IL8 stimulation of OEC migratory
capacity, although significant, was minor (sixfold lower)
when compared to VEGF treatment. Our study has used IL8
concentrations ranging from 1 to 100 ng/mL, and results
indicate that recombinant human IL8 does not promote OEC
proliferation or migration at these doses. However, OEC
tube forming capacity was significantly enhanced by 1 ng/
mL IL8, but only in lower passage cells (up to passage P25)
as higher passage OECs showed no angiogenic response
when exposed to IL8. Our results underscore the complexity
of the angiogenic process, and when dissected in its compo-
nents, IL8 showed no effect upon OECs proliferation and
migration; however, tubulogenesis in low-passage OECs was
clearly enhanced by low concentrations of IL8. In summary,
a proangiogenic role for exogenous IL8 in these highly
proliferative OECs seems minor, while its intrinsic role as
senescence facilitator is major and strongly supported by our
data.
CONCLUSIONS
In conclusion, this work reveals that ex vivo expansion of
human OECs ultimately leads to replicative senescence linked
to cellular dysfunction. An inflammatory cytokine component
was unequivocally identified as part of the OEC senescence
program. Silencing IL8 expression in OECs resulted in delay
of senescence and extension of OECs ex vivo lifespan which
could have benefits in the context of vasoreparative or tissue
engineering cell therapy.
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